|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
重组全人源抗CD39单克隆抗体JS019单药在晚期实体瘤患者中的安全性、耐受性、药代动力学特征和初步有效性的I期临床研究
[Translation] A phase I clinical study of the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of the recombinant fully human anti-CD39 monoclonal antibody JS019 in patients with advanced solid tumors
评价JS019单药在晚期恶性实体瘤患者中的安全性和耐受性;
确定JS019单药的最大耐受剂量(MTD)或最佳生物效应剂量(OBD)和II期临床研究推荐剂量(RP2D)
评价JS019单药在晚期恶性实体瘤患者中的药代动力学(PK)特征
评价JS019单药在晚期恶性实体瘤患者中的免疫原性;
评价JS019单药在晚期恶性实体瘤患者体内的药效学特征;
初步评估JS019单药治疗晚期恶性实体瘤的有效性。
[Translation] Evaluate the safety and tolerability of JS019 monotherapy in patients with advanced malignant solid tumors;
Determine the maximum tolerated dose (MTD) or best biological effect dose (OBD) of JS019 monotherapy and the recommended dose (RP2D) for Phase II clinical studies
Evaluate the pharmacokinetic (PK) characteristics of JS019 monotherapy in patients with advanced malignant solid tumors
Evaluate the immunogenicity of JS019 monotherapy in patients with advanced malignant solid tumors;
Evaluate the pharmacodynamic characteristics of JS019 monotherapy in patients with advanced malignant solid tumors;
Preliminary evaluation of the effectiveness of JS019 monotherapy in the treatment of advanced malignant solid tumors.
重组全人源抗CD39单克隆抗体JS019单药在晚期实体瘤或淋巴瘤患者中的安全性、耐受性、药代动力学特征和初步有效性的I期临床研究
[Translation] A phase I clinical study of the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of JS019, a recombinant fully human anti-CD39 monoclonal antibody, in patients with advanced solid tumors or lymphomas
评价JS019单药在晚期恶性实体瘤/淋巴瘤患者中的安全性和耐受性;
确定JS019单药的最大耐受剂量(MTD,如果可能)和II期临床研究推荐剂量(RP2D)
评价JS019单药在晚期恶性实体瘤/淋巴瘤患者中的药代动力学(PK)特征;
评价JS019单药在晚期恶性实体瘤/淋巴瘤患者中的免疫原性;
评价JS019单药在晚期恶性实体瘤/淋巴瘤患者体内的药效学特征;
初步评估JS019单药治疗晚期恶性实体瘤/淋巴瘤的有效性
探索相关生物标志物与疗效间的相关性
[Translation] Evaluate the safety and tolerability of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas;
Determine the maximum tolerated dose (MTD, if possible) and recommended dose (RP2D) of JS019 monotherapy for Phase II clinical studies
Evaluate the pharmacokinetic (PK) characteristics of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas;
Evaluate the immunogenicity of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas;
Evaluate the pharmacodynamic characteristics of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas;
Preliminary evaluation of the effectiveness of JS019 monotherapy in the treatment of advanced malignant solid tumors/lymphomas
Explore the correlation between relevant biomarkers and efficacy
100 Clinical Results associated with Suzhou Kebrijun Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Suzhou Kebrijun Biomedical Technology Co., Ltd.
100 Deals associated with Suzhou Kebrijun Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Suzhou Kebrijun Biomedical Technology Co., Ltd.